Answers are grounded in this paper and cite their sources.
Background The melanocortin α-melanocyte stimulating hormone (α-MSH), an endogenous peptide with high affinity for the melanocortin 1 receptor (MC1r), has demonstrated prevention and reversal of intestinal and ocular inflammation in animal models. Preclinical studies were performed to determine whether two MC1r receptor agonists, PL-8177 and PL-8331, exhibit actions and efficacy similar to α-MSH in preventing and reversing intestinal and ocular inflammation. Methods Both PL-8177 and PL-8331 were assessed in a Eurofins LeadProfilingScreen selectivity panel including 72 in vitro assays. PL-8177 was evaluated in an in vitro assay using human whole blood stimulated by lipopolysaccharide to determine inhibition of tumor necrosis factor alpha (TNF-α); for comparison, adrenocorticotrophic hormone (ACTH) and α-MSH were used as positive controls. PL-8177, dosed at 0.5 µg, 1.5 µg, and 5.0 µg, was assessed in a cannulated rat model of dinitrobenzene sulfonic acid (DNBS)-induced bowel inflammation and versus vehicle and oral sulfasalazine. PL-8177 was also dosed at 0.3 mg/kg/mouse injected intraperitoneally versus untreated controls and α-MSH treatment in mice with experimental autoimmune uveitis (EAU). PL-8331 at 3 dose levels, 3 times daily, was evaluated in a murine model of scopolamine-induced dry eye disease (SiccaSystem™ model), compared with twice-daily Restasis® and Xiidra®. Results Both PL-8177 and PL-8331 demonstrated no significant activity at the 10 μᴍ level in any of the 72 in vitro assays. PL-8177 inhibited lipopolysaccharide-induced TNF-α to a similar degree as ACTH and α-MSH. In the DNBS rat model of bowel inflammation, PL-8177 was significantly superior to untreated controls at all 3 doses (P<0.05) in reducing bowel inflammation parameters, with effects similar to sulfasalazine. In the murine EAU model, PL-8177 significantly reduced retinal inflammation scores versus untreated controls (P = 0.0001) over 3 to 5 weeks, and to a similar degree as α-MSH. In the murine scopolamine-induced model of dry eye disease, PL-8331 reduced corneal fluorescein staining scores at all doses, significantly (P = 0.02) for the highest dose (1 x 10-5 mg·mL-1), and similarly to Restasis®; Xiidra® demonstrated no effect. Conclusions The MC1r receptor agonists PL-8177and PL-8331exhibited actions similar to those of α-MSH in preventing and reversing intestinal and ocular inflammation in preclinical disease models.
No takes yet. Share an insight, caveat, or question.
Spana et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: